Sara Blasco-Turrión, Kasparas Briedis, Rodrigo Estévez-Loureiro, Angel Sánchez-Recalde, Ignacio Cruz-González, Isaac Pascual, Julia Mascherbauer, Omar Abdul-Jawad Altisent, Luis Nombela-Franco, Manuel Pan, Ramiro Trillo, Raul Moreno, Georg Delle Karth, Juan Pablo Sánchez-Luna, Jose Carlos Gonzalez-Gutiérrez, Ana Revilla-Orodoea, Jose Luis Zamorano, Itziar Gómez-Salvador, Rishi Puri, J Alberto San Román, Ignacio J Amat-Santos
BACKGROUND: Several orthotopic transcatheter strategies have been developed to treat severe tricuspid regurgitation (TR); however, many patients are deemed unsuitable. Caval valve implantation with the TricValve system addresses this unmet need. OBJECTIVES: This study sought to determine the impact of TricValve on systemic congestion and quality of life (QOL) at 1 year. METHODS: The TRICUS (Safety and Efficacy of the TricValve® Transcatheter Bicaval Valves System in the Superior and Inferior Vena Cava in Patients With Severe Tricuspid Regurgitation) and TRICUS EURO studies were prospective, nonblinded, nonrandomized, single-arm trials representing the early-in-man experience of the TricValve system in NYHA functional class III or IV severe TR patients, optimally medicated and ineligible for open heart surgery, with significant caval backflow...
January 8, 2024: JACC. Cardiovascular Interventions